---
title: "Impedimed cancels lapsed options and performance rights, clarifying capital structure"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291624751.md"
description: "Impedimed Limited (AU:IPD) announced the lapse of 11,642,750 options and 8,529,911 performance rights due to unmet conditions. This reduces potential future dilution and clarifies the company's capital structure. The move aims to align reported capital with current realities and reset equity-based incentives. Analysts currently rate the stock as a Buy with a A$0.02 price target."
datetime: "2026-07-03T05:24:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291624751.md)
  - [en](https://longbridge.com/en/news/291624751.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291624751.md)
generator: "portal-rs"
---

# Impedimed cancels lapsed options and performance rights, clarifying capital structure

Impedimed Limited ( (AU:IPD) ) has issued an update.

Impedimed Limited has announced the cessation of 11,642,750 options and 8,529,911 performance rights after the conditions attached to these securities were not met or became incapable of being satisfied by 30 June 2026. The lapse of these conditional securities effectively reduces the company’s potential future dilution, clarifies its issued capital structure, and may signal a reset of its equity-based incentive arrangements for management and staff.

The move provides investors with greater transparency over Impedimed’s capital base and the status of its long-term incentive instruments. By formally recording the expiry of these options and performance rights, the company aligns its reported capital position with current realities, which may influence perceptions of future share supply and the alignment of executive incentives with shareholder interests.

The most recent analyst rating on (AU:IPD) stock is a Buy  
 with a A$0.02 price target.  
 To see the full list of analyst forecasts on Impedimed Limited stock,  
 see the AU:IPD Stock Forecast page. 

**More about Impedimed Limited**

Impedimed Limited is an Australian-listed medical technology company, trading under the ASX code IPD. The company develops diagnostic and monitoring solutions, with its securities structure including options and performance rights tied to specific performance and vesting conditions for employees and stakeholders.

**Average Trading Volume:** 4,717,878

**Technical Sentiment Signal:** Sell

**Current Market Cap:** A$21.96M

Learn more about IPD stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [IPD.AU](https://longbridge.com/en/quote/IPD.AU.md)

## Related News & Research

- [ImpediMed lodges 2026 Corporate Governance Statement and Appendix 4G](https://longbridge.com/en/news/297105943.md)
- [IPD: Q4 FY26 delivered revenue growth, strong cash position, and expanded reimbursement coverage](https://longbridge.com/en/news/293982328.md)
- [Macquarie Keeps Their Hold Rating on Region Group (SCPAF)](https://longbridge.com/en/news/298185411.md)
- [Simon Henry Spends AU$97k On DGL Group Stock](https://longbridge.com/en/news/298361741.md)
- [Macquarie Reaffirms Their Buy Rating on Megaport (MGPPF)](https://longbridge.com/en/news/298158915.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**